Skip to main content

Table 2 Cabazitaxel exposure

From: Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study

 

All patients

Unmatched patients

Matched patients

C20

C25

C20

C25

N

660

190

159

112

112

Number of cycles

 Mean ± SD

5.5 ± 4.1

4.9 ± 3.7

5.8 ± 4.2

5.1 ± 3.7

5.9 ± 4.3

 Median (range)

4.0 (1–18)

4.0 (1–15)

4.0 (1–16)

4.0 (1–15)

4.0 (1–16)

Duration of treatment (days)

 Mean ± SD

152.9 ± 119.2

134.9 ± 103.3

159.3 ± 121.6

138.5 ± 104.2

166.0 ± 126.5

 Median (range)

106 (21–385)

103 (21–384)

110 (21–385)

112 (21–384)

110 (21–385)

Cumulative dose (mg/m2)

 Mean ± SD

114.4 ± 88.7

96.7 ± 71.2

134.5 ± 99.2

100.6 ± 72.7

136.4 ± 101.5

 Median (range)

84.4 (10–445)

69.2 (20–300)

100.0 (25–400)

80 (20–300)

100 (25–400)

ADI (mg/m2/week)

 Mean ± SD

5.7 ± 1.4

5.4 ± 1.0

6.5 ± 1.5

5.4 ± 0.9

6.4 ± 1.5

 Median (range)

5.6 (1.5–8.4)

5.4 (2.4–6.9)

6.6 (2.2–8.4)

5.5 (2.4–6.7)

6.4 (2.2–8.4)

RDI(%)

 Mean ± SD

68.0 ± 16.4

64.6 ± 11.6

78.3 ± 17.7

65.1 ± 11.3

76.6 ± 18.4

 Median (range)

67.2 (17.8–101.0)

64.6 (28.4–82.6)

79.2 (26.3–101.0)

65.9 (28.4–80.5)

77.0 (26.3–101.0)

  1. C20 20 mg/m2 cabazitaxel, C25 25 mg/m2 cabazitaxel, SD Standard deviation, ADI Actual dose intensity, RDI Relative dose intensity (planned dose intensity = 8.33 mg/m2/week)